Annual CFO
-$594.74 M
-$80.99 M-15.76%
31 December 2023
Summary:
Apellis Pharmaceuticals annual cash flow from operations is currently -$594.74 million, with the most recent change of -$80.99 million (-15.76%) on 31 December 2023. During the last 3 years, it has fallen by -$434.25 million (-270.58%). APLS annual CFO is now -17165.22% below its all-time high of -$3.44 million, reached on 31 December 2013.APLS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$34.10 M
+$42.44 M+508.87%
30 September 2024
Summary:
Apellis Pharmaceuticals quarterly cash flow from operations is currently $34.10 million, with the most recent change of +$42.44 million (+508.87%) on 30 September 2024. Over the past year, it has increased by +$203.18 million (+120.17%). APLS quarterly CFO is now -75.99% below its all-time high of $141.98 million, reached on 31 December 2020.APLS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$205.10 M
+$203.18 M+49.76%
30 September 2024
Summary:
Apellis Pharmaceuticals TTM cash flow from operations is currently -$205.10 million, with the most recent change of +$203.18 million (+49.76%) on 30 September 2024. Over the past year, it has increased by +$432.50 million (+67.83%). APLS TTM CFO is now -2333.88% below its all-time high of -$8.43 million, reached on 31 March 2017.APLS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
APLS Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -15.8% | +120.2% | +67.8% |
| 3 y3 years | -270.6% | +120.2% | +33.5% |
| 5 y5 years | -353.2% | +163.6% | -18.2% |
APLS Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -270.6% | at low | at high | +119.2% | at high | +67.8% |
| 5 y | 5 years | -353.2% | at low | -76.0% | +119.2% | -27.8% | +67.8% |
| alltime | all time | <-9999.0% | at low | -76.0% | +119.2% | -2333.9% | +67.8% |
Apellis Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $34.10 M(-508.9%) | -$205.10 M(-49.8%) |
| June 2024 | - | -$8.34 M(-93.7%) | -$408.28 M(-25.8%) |
| Mar 2024 | - | -$132.98 M(+35.9%) | -$550.10 M(-7.5%) |
| Dec 2023 | -$594.74 M(+15.8%) | -$97.88 M(-42.1%) | -$594.74 M(-6.7%) |
| Sept 2023 | - | -$169.09 M(+12.6%) | -$637.60 M(+2.4%) |
| June 2023 | - | -$150.16 M(-15.5%) | -$622.94 M(+7.4%) |
| Mar 2023 | - | -$177.62 M(+26.2%) | -$579.80 M(+12.9%) |
| Dec 2022 | -$513.75 M(-8.8%) | -$140.74 M(-8.9%) | -$513.75 M(+5.8%) |
| Sept 2022 | - | -$154.42 M(+44.3%) | -$485.50 M(-2.8%) |
| June 2022 | - | -$107.02 M(-4.1%) | -$499.71 M(-4.2%) |
| Mar 2022 | - | -$111.56 M(-0.8%) | -$521.37 M(-7.4%) |
| Dec 2021 | -$563.13 M(+250.9%) | -$112.50 M(-33.3%) | -$563.13 M(+82.4%) |
| Sept 2021 | - | -$168.63 M(+31.0%) | -$308.65 M(+28.7%) |
| June 2021 | - | -$128.69 M(-16.1%) | -$239.85 M(+16.7%) |
| Mar 2021 | - | -$153.31 M(-208.0%) | -$205.45 M(+28.0%) |
| Dec 2020 | -$160.49 M | $141.98 M(-242.2%) | -$160.49 M(-58.3%) |
| Sept 2020 | - | -$99.82 M(+5.9%) | -$384.54 M(+13.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2020 | - | -$94.29 M(-13.0%) | -$338.31 M(+19.2%) |
| Mar 2020 | - | -$108.35 M(+32.0%) | -$283.92 M(+34.5%) |
| Dec 2019 | -$211.13 M(+60.9%) | -$82.07 M(+53.1%) | -$211.13 M(+21.7%) |
| Sept 2019 | - | -$53.60 M(+34.3%) | -$173.54 M(+13.4%) |
| June 2019 | - | -$39.91 M(+12.2%) | -$153.08 M(+6.4%) |
| Mar 2019 | - | -$35.56 M(-20.1%) | -$143.87 M(+9.6%) |
| Dec 2018 | -$131.24 M(+181.7%) | -$44.48 M(+34.2%) | -$131.24 M(+28.3%) |
| Sept 2018 | - | -$33.13 M(+7.9%) | -$102.30 M(+27.4%) |
| June 2018 | - | -$30.69 M(+33.8%) | -$80.30 M(+31.4%) |
| Mar 2018 | - | -$22.94 M(+47.7%) | -$61.10 M(+31.1%) |
| Dec 2017 | -$46.60 M(+79.2%) | -$15.53 M(+39.5%) | -$46.60 M(+50.0%) |
| Sept 2017 | - | -$11.14 M(-3.1%) | -$31.06 M(+55.9%) |
| June 2017 | - | -$11.50 M(+36.4%) | -$19.92 M(+136.4%) |
| Mar 2017 | - | -$8.43 M | -$8.43 M |
| Dec 2016 | -$26.00 M(+37.9%) | - | - |
| Dec 2015 | -$18.86 M(+89.6%) | - | - |
| Dec 2014 | -$9.95 M(+188.8%) | - | - |
| Dec 2013 | -$3.44 M | - | - |
FAQ
- What is Apellis Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals annual CFO year-on-year change?
- What is Apellis Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals quarterly CFO year-on-year change?
- What is Apellis Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals TTM CFO year-on-year change?
What is Apellis Pharmaceuticals annual cash flow from operations?
The current annual CFO of APLS is -$594.74 M
What is the all time high annual CFO for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high annual cash flow from operations is -$3.44 M
What is Apellis Pharmaceuticals annual CFO year-on-year change?
Over the past year, APLS annual cash flow from operations has changed by -$80.99 M (-15.76%)
What is Apellis Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of APLS is $34.10 M
What is the all time high quarterly CFO for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high quarterly cash flow from operations is $141.98 M
What is Apellis Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, APLS quarterly cash flow from operations has changed by +$203.18 M (+120.17%)
What is Apellis Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of APLS is -$205.10 M
What is the all time high TTM CFO for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high TTM cash flow from operations is -$8.43 M
What is Apellis Pharmaceuticals TTM CFO year-on-year change?
Over the past year, APLS TTM cash flow from operations has changed by +$432.50 M (+67.83%)